Doxorubicin Liposomal 20 Mg/10 Ml & 50 Mg/25 Ml Accord 20 mg/10 ml & 50 mg/25 ml Concentrate for solution for infusion
PDF Leaflet Revision Date: 11 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Metastatic breast cancer, advanced ovarian cancer, multiple myeloma, AIDS-related Kaposi's sarcoma.
Dosage (summary)
50 mg/mu00b2 every 4 weeks for breast/ovarian cancer; 30 mg/mu00b2 on day 4 of bortezomib regimen; 20 mg/mu00b2 every 2-3 weeks for AIDS-KS.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Caution with other cytotoxic agents
- May enhance toxicity of other anti-cancer therapies
Contraindications
- Hypersensitivity to doxorubicin
- Pregnancy
- Breastfeeding
- Patients <18 years
Common side effects
- Neutropenia
- Nausea
- Fatigue
- Stomatitis
- Palmar-plantar erythrodysaesthesia
Counselling Points
- Avoid pregnancy during treatment
- Monitor for infusion reactions
- Report any severe side effects immediately
Serious warnings
- Cardiac toxicity
- Myelosuppression
- Infusion reactions
Important Disclaimer
The Doxorubicin Liposomal 20 Mg/10 Ml & 50 Mg/25 Ml Accord 20 mg/10 ml & 50 mg/25 ml Concentrate for solution for infusion professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
